Topical composition

1. A composition for topical application comprising a polyaphron dispersion, wherein the polyaphron dispersion comprises a continuous phase, a discontinuous phase and crisaborole,

wherein the discontinuous phase comprises an oil, and

wherein the oil comprises diisopropyl adipate and/or diethyl sebacate and/or dibutyl adipate.

2. A composition according to claim 1 , wherein the crisaborole is present in an amount of from 1 to 5 wt % by weight of the composition.

3. A composition according to claim 1 , wherein the crisaborole is predominantly in the discontinuous phase, or wherein the crisaborole is predominantly in the continuous phase.

4. A composition according to claim 1 , wherein the discontinuous phase is present in an amount of at least 50 wt % by weight of the composition.

5. A composition according to claim 1 , wherein the diisopropyl adipate and/or diethyl sebacate and/or dibutyl adipate are present in a total amount of at least 60 wt % by weight of the discontinuous phase.

6. A composition according to claim 1 , wherein the discontinuous phase comprises an oil, and the oil comprises, by weight of the composition:

(i) diisopropyl adipate in an amount of from 5 to 45 wt %;

(ii) diethyl sebacate and/or dibutyl adipate in a total amount of from 5 to 45 wt %; and

(iii) castor oil and/or caprylic/capric triglycerides in a total amount of from 5 to 45 wt %.

7. A composition according to claim 1 , wherein the continuous phase comprises at least 50 wt % by weight of the continuous phase of a polar water-miscible solvent selected from the group consisting of C 1 -C 4 alcohols, polyethylene glycol, ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, glycerol, diethylene glycol mono ethyl ether, propylene carbonate and mixtures of two or more thereof.

8. A composition according to claim 1 , having a total surfactant content of less than 5 wt % by weight of the composition.

9. A composition according to claim 1 , wherein the composition comprises at least 10 wt % water by weight of the composition.

10. A composition according to claim 1 , wherein the composition is in the form of a lotion or cream.

11. A composition according to claim 1 , wherein at least 95 wt % of the crisaborole is dissolved in the composition.

12. A composition according to claim 1 , wherein the composition is chemically and/or physically stable for at least 12 months at 25° C.±2° C., as measured at 60% RH±5%; and/or wherein the composition is chemically and/or physically stable for at least 6 months at 40° C.±3° C., as measured at 60% RH±5%.

13. A composition according to claim 1 , comprising, by weight of the composition:

from 2 to 4 wt % crisaborole, and

at least 60 wt % discontinuous phase comprising an oil;

wherein the crisaborole is predominantly in the discontinuous phase,

wherein the oil comprises at least 60 wt % diisopropyl adipate by weight of the discontinuous phase, and

wherein the composition is in the form of a lotion or cream.

14. A composition according to claim 1 , comprising, by weight of the composition:

from 2 to 4 wt % crisaborole, and

at least 40 wt % continuous aqueous phase;

wherein the crisaborole is predominantly in the continuous aqueous phase,

wherein the continuous aqueous phase comprises at least 60 wt % propylene glycol by weight of the continuous aqueous phase, and

wherein the composition is in the form of a lotion or cream.

15. A composition according to claim 1 , for use in the treatment of the human or animal body by therapy.

16. A composition according to claim 1 for use in the treatment of atopic dermatitis or psoriasis.

17. A composition according to claim 1 , wherein the crisaborole is present in an amount of from 2 to 4 wt % by weight of the composition.

18. A composition according to claim 1 , having a total surfactant content of less than 1 wt % by weight of the composition.

19. A composition according to claim 1 , having a total surfactant content of less than 0.5 wt % by weight of the composition.